ArticleAnnals of hematology2021

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.

Martin Kaiser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.